Other approaches specifically targeting the hepcidin/ferroportin pathway in CKD are in various stages of clinical development, and include monoclonal antibodies targeting the positive regulators of hepcidin, including BMP6 (32) and hemojuvelin (33), and monoclonal antibodies against the hepcidin receptor and iron transporter ferroportin (32). This evidence concerns the gene HAMP and chronic kidney disease.